Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant.

Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK.

Ther Adv Psychopharmacol. 2016 Apr;6(2):99-144. doi: 10.1177/2045125316629071. Epub 2016 Feb 18. Review.

2.

Neuropeptide Trefoil Factor 3 Reverses Depressive-Like Behaviors by Activation of BDNF-ERK-CREB Signaling in Olfactory Bulbectomized Rats.

Li J, Luo Y, Zhang R, Shi H, Zhu W, Shi J.

Int J Mol Sci. 2015 Nov 30;16(12):28386-400. doi: 10.3390/ijms161226105.

3.

Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?

Sharma H, Santra S, Dutta A.

Future Med Chem. 2015;7(17):2385-406. doi: 10.4155/fmc.15.134. Epub 2015 Nov 30. Review.

4.

Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics.

de Sousa RT, Zanetti MV, Brunoni AR, Machado-Vieira R.

Curr Neuropharmacol. 2015;13(5):616-35. Review.

5.

Antidepressants: relationship to the time to psychiatric readmission and probability of being in hospital in depressive patients.

Warnke I, Nordt C, Moock J, Kawohl W, Rössler W.

Front Public Health. 2014 May 8;2:40. doi: 10.3389/fpubh.2014.00040. eCollection 2014.

6.

Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study.

Franco-Chaves JA, Mateus CF, Luckenbaugh DA, Martinez PE, Mallinger AG, Zarate CA Jr.

J Affect Disord. 2013 Jul;149(1-3):319-25. doi: 10.1016/j.jad.2013.02.003. Epub 2013 Mar 18.

7.

Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial.

Dunlop BW, Binder EB, Cubells JF, Goodman MM, Kelley ME, Kinkead B, Kutner M, Nemeroff CB, Newport DJ, Owens MJ, Pace TW, Ritchie JC, Rivera VA, Westen D, Craighead WE, Mayberg HS.

Trials. 2012 Jul 9;13:106. doi: 10.1186/1745-6215-13-106.

9.

Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder.

Gertsik L, Poland RE, Bresee C, Rapaport MH.

J Clin Psychopharmacol. 2012 Feb;32(1):61-4. doi: 10.1097/JCP.0b013e31823f3b5f.

10.

Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder.

Dunlop BW, Kelley ME, Mletzko TC, Velasquez CM, Craighead WE, Mayberg HS.

J Psychiatr Res. 2012 Mar;46(3):375-81. doi: 10.1016/j.jpsychires.2011.11.003. Epub 2011 Nov 26. Erratum in: J Psychiatr Res. 2014 Jul;54:141.

11.

Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study.

Thase ME, Ninan PT, Musgnung JJ, Trivedi MH.

Prim Care Companion CNS Disord. 2011;13(1). pii: PCC.10m00979. doi: 10.4088/PCC.10m00979blu.

12.

Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample.

Vitiello B, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller MB, Birmaher B, Ryan ND, Kennard B, Mayes TL, DeBar L, Lynch F, Dickerson J, Strober M, Suddath R, McCracken JT, Spirito A, Onorato M, Zelazny J, Porta G, Iyengar S, Brent DA.

J Clin Psychiatry. 2011 Mar;72(3):388-96. doi: 10.4088/JCP.09m05885blu.

13.

Synthesis and structure-activity studies of benzyl ester meperidine and normeperidine derivatives as selective serotonin transporter ligands.

Gu X, Izenwasser S, Wade D, Housman A, Gulasey G, Rhoden JB, Savoie CD, Mobley DL, Lomenzo SA, Trudell ML.

Bioorg Med Chem. 2010 Dec 1;18(23):8356-64. doi: 10.1016/j.bmc.2010.09.060. Epub 2010 Sep 29.

14.
15.

Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.

Leonard B, Taylor D.

J Psychopharmacol. 2010 Aug;24(8):1143-52. doi: 10.1177/0269881109349835. Epub 2010 Feb 10. Review.

16.

Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study.

Martinez C, Assimes TL, Mines D, Dell'aniello S, Suissa S.

BMJ. 2010 Feb 5;340:c249. doi: 10.1136/bmj.c249.

17.

Triple reuptake inhibitors: a premise and promise.

Marks DM, Pae CU, Patkar AA.

Psychiatry Investig. 2008 Sep;5(3):142-7. doi: 10.4306/pi.2008.5.3.142. Epub 2008 Sep 30.

18.

Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes.

Kaur H, Izenwasser S, Verma A, Wade D, Housman A, Stevens ED, Mobley DL, Trudell ML.

Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8. doi: 10.1016/j.bmcl.2009.10.087. Epub 2009 Oct 23.

19.

A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).

Meyers BS, Flint AJ, Rothschild AJ, Mulsant BH, Whyte EM, Peasley-Miklus C, Papademetriou E, Leon AC, Heo M; STOP-PD Group.

Arch Gen Psychiatry. 2009 Aug;66(8):838-47. doi: 10.1001/archgenpsychiatry.2009.79. Erratum in: Arch Gen Psychiatry. 2011 Jun;68(6):626.

20.

Triple reuptake inhibitors: the next generation of antidepressants.

Marks DM, Pae CU, Patkar AA.

Curr Neuropharmacol. 2008 Dec;6(4):338-43. doi: 10.2174/157015908787386078.

Supplemental Content

Support Center